Deferoxamine.
| Characteristics | |
| Route of Administration | SQ, IV |
| Half-life | 20 minutes |
| Primary routes of iron excretion | Urine/Stool |
| Dose range | 20–60 mg/kg/d |
| Guidelines for Monitoring Therapy | |
| Audiometry and eye exams annually | |
| Serum ferritin level quarterly | |
| Assessment of liver iron annually | |
| Assessment of cardiac iron annually after 10 years of age | |
| Advantages | |
| Long-term experience | |
| Effective in maintaining normal or near normal iron stores | |
| Reversal of cardiac disease with intensive therapy | |
| May be combined with deferiprone | |
| Disadvantages | |
| Requires parenteral infusion | |
| Ear, eye, bone toxicity | |
| Poor compliance | |
| Characteristics | |
| Route of Administration | SQ, IV |
| Half-life | 20 minutes |
| Primary routes of iron excretion | Urine/Stool |
| Dose range | 20–60 mg/kg/d |
| Guidelines for Monitoring Therapy | |
| Audiometry and eye exams annually | |
| Serum ferritin level quarterly | |
| Assessment of liver iron annually | |
| Assessment of cardiac iron annually after 10 years of age | |
| Advantages | |
| Long-term experience | |
| Effective in maintaining normal or near normal iron stores | |
| Reversal of cardiac disease with intensive therapy | |
| May be combined with deferiprone | |
| Disadvantages | |
| Requires parenteral infusion | |
| Ear, eye, bone toxicity | |
| Poor compliance | |